Background: Cognitive impairment in schizophrenia-spectrum disorders is highly prevalent and notably influences functional outcomes.
Aims: To characterise the cognitive effectiveness of second-generation antipsychotic drugs.
Method: One hundred consecutive and previously unmedicated patients with first-episode schizophrenia-spectrum disorders were admitted.